Ann: Imugene Receives A$20 million for Convertible Notes Issuance, page-63

I never stated any such thing. You should focus on reading the terms of this deal before spouting off in other areas you have zero comprehension in.

If IMU was undervalued they wouldn't be taking bottom of the barrel deals from vulture capitalists.

If CF33 had shown broad utility in solid tumours it would have been licensed and this raise wouldn't have been required.

If Azer-Cel had demonstrated responses outside a niche indication it would have been licensed and this raise wouldn't have been required.

If the B Cell Platform was worth anything at all it would have sold by now and this raise wouldn't have been required.